Novartis' Beovu safety woes could cost billions of dollars, ...

The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels.

More pressure on Bayer as EU approves Novartis' Beovu in wet...

The market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular or “wet” age-related macular degeneration, offering a less frequent dosing

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejec...

AI specialist Exscientia signs drug discovery tie-up with Ba...

Novartis’ blockbuster hope Beovu clears EMA advisory panel

SidekickHealth begins PAD partnership with Bayer

Nordic digital therapeutics company SidekickHealth has begun a strategic partnership with German pharma Bayer to provide a digital medication management and lifestyle change platform to pat